Christopher Schreiber
About Christopher Schreiber
Independent Supervisory Board member of Sono Group N.V. (SEVCF), appointed January 31, 2024; term expires in 2026; age 60 . Background spans three decades in the securities industry with prior executive and board roles at Akers Bio and MyMD Pharmaceuticals (NASDAQ: MYMD), capital markets leadership at Taglich Brothers, and board service at Paulson Investment Company; B.A. in Political Science, Johns Hopkins University .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Akers Bio | Executive Chair (prior role) | Not disclosed | Capital markets/board leadership |
| MyMD Pharmaceuticals (NASDAQ: MYMD) | Board Member (prior role) | Not disclosed | Public company governance |
| Taglich Brothers, Inc. | Managing Director, Capital Markets | Not disclosed | Deal structuring and syndication |
| Paulson Investment Company | Board Member (prior role) | Not disclosed | Investment banking board experience |
External Roles
| Organization | Role | Sector/Type |
|---|---|---|
| Long Island Express North | Director and Partner | Private/Elite sports training |
| Fox Lane Youth Lacrosse | Volunteer Board Member | Non-profit/Youth sports |
Board Governance
- Board composition and tenure: Supervisory Board of three members (David Dodge – Chair; Christopher Schreiber; Owen May); Schreiber appointed Jan 31, 2024, term through 2026 .
- Committee assignments: Audit Committee currently comprises the entire Supervisory Board; Schreiber is therefore a member. David Dodge serves as Audit Committee Chair; all members are independent per OTCQB and SEC Rule 10A‑3; audit committee financial expert designated (Dodge) .
- Nomination process: Nominations are delegated to the nomination and corporate governance committee per its charter; (membership not disclosed in the filing) .
- Independence: Appointed as an independent Supervisory Board member; audit committee independence affirmed .
- Attendance/engagement: Not disclosed in the 10-K/DEF 14A (no attendance rates provided).
Fixed Compensation
| Component | Policy/Amount | Period/Notes |
|---|---|---|
| Annual cash retainer (non‑executive director) | $50,000 | Effective Feb 1, 2024 |
| Fees earned (Schreiber) | $45,837 | FY2024 fees paid in cash (no equity) |
- No additional committee fees were disclosed for 2024 under the new $50,000 flat retainer structure .
Performance Compensation
- Directors received no stock or option awards in 2024; no performance‑based or equity components disclosed for directors .
Other Directorships & Interlocks
| Company/Entity | Role | Public/Private | Potential Interlock/Conflict Notes |
|---|---|---|---|
| Akers Bio | Former Executive Chair | Public (historical) | None disclosed with Sono |
| MyMD Pharmaceuticals | Former Board Member | Public | None disclosed with Sono |
| Paulson Investment Company | Former Board Member | Private/Financial | None disclosed with Sono |
| Taglich Brothers, Inc. | Managing Director, Capital Markets | Private/Financial | None disclosed with Sono |
No related‑party transactions involving Schreiber are disclosed in Item 13; related‑party notes focus on Yorkville financings and SVSE pledges, not directors other than management .
Expertise & Qualifications
- Capital markets, deal structuring, and syndication expertise from senior roles at investment firms .
- Public company board and chair experience (Akers Bio; MyMD Pharmaceuticals) .
- Audit committee member; board determined all audit members are financially literate; an audit committee financial expert is designated on the committee (Dodge) .
- Education: B.A., Johns Hopkins University .
Equity Ownership
| Metric | As of Mar 24, 2025 | As of Jun 30, 2025 |
|---|---|---|
| Ordinary Shares owned | 0 | 0 |
| High Voting Shares owned | 0 | 0 |
| % of Ordinary Shares outstanding | 0% | 0% |
| % of High Voting Shares outstanding | 0% | 0% |
- Company policy prohibits pledging and hedging of company securities by insiders; no pledging or hedging by Schreiber is disclosed .
Governance Assessment
-
Strengths:
- Independent director with substantive public company and capital markets experience; member of an all‑independent audit committee .
- Cash-only director pay (no equity in 2024) reduces risk of short‑term equity incentives; total annual retainer structure is transparent .
- Company has adopted a clawback policy (executive-focused) and an insider trading policy prohibiting pledging and hedging, supporting broader governance controls .
-
Alignment concerns / red flags for investors:
- Zero reported share ownership by Schreiber; limited “skin-in-the-game” alignment for this director .
- Concentration of control at the company level: SVSE LLC (beneficially controlled by the CEO) holds 16.4% of ordinary shares and 100% of high voting shares, resulting in 51.1% combined voting power; those securities are pledged to Yorkville, introducing counterparty/control risk if defaults occur .
- Small board with Audit Committee comprised of the entire board — efficient for size but less segregation of oversight than larger boards; Audit Chair is designated and independent .
- Company‑level going‑concern and financing dependencies (Yorkville commitments, pending conversions, uplisting conditions) create a stressed governance context; while not specific to Schreiber, it elevates board oversight risk .
Overall, Schreiber brings capital markets and board experience and meets independence and audit committee standards. However, lack of personal share ownership and the company’s control/voting structure and financing dependencies are broader governance risks investors should monitor.